Oxford spinout Alethio Therapeutics closed a $90 million Series A to take ATX-011, a monoclonal antibody against the G6B receptor, into Phase 1/2a studies in essential thrombocythemia. It is also developing a G6B-targeted ADC for myelofibrosis.
|Articles|March 24, 2022
Roquette Invests €25 million for Polyols at its Site in Lestrem, France
Author(s)BioPharm International Editors
Roquette is investing €25 million at its site in Lestrem, France to strengthen its position in the polyols market.
Advertisement
Roquette, a company focused on providing plant-based ingredients, plant proteins, and pharmaceutical excipients, announced on March 22, 2022 an investment plan for €25 million (approximately USD $27.5 million) for liquid and powder polyols between 2022 and 2024 at its site in Lestrem, France. The investment will establish a strong, reliable supply for the future and strengthen the company’s position as a leader in the polyols market.
Polyols are key pharmaceutical excipients in oral dosage forms. They are directly compressible and aid in the formulation of swallowable, chewable, or dispersible tablets. The higher purity grades of polyols are also APIs and are widely used in injectable solutions. They are also used in oral care applications because of their functionalities as non-crystallizing humectant, non-cariogenic, or shelf-life enhancer.
The investment will improve equipment efficiency, increase safety standards, standardize industrial operations, and improve overall production performance. The investment will also ensure a sustainable supply of polyols in the market and meet customers’ increasing expectations for greater flexibility.
Source:
Advertisement
Related to this article
T-Therapeutics closed an oversubscribed $133 million Series B backed by Eli Lilly, JJDC, and others. The funding will take its first T-cell receptor bispecifics in cancer and autoimmune disease into clinical trials.
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
FDA’s draft framework would let sponsors add patient-specific genome editing variants to an approved BLA using in vitro data. Here is what the guidance proposes, what evidence it asks for, and what remains unresolved.
Healthy-volunteer data show sustained TL1A suppression and a profile supporting infrequent subcutaneous dosing. Caldera also licensed a second bispecific, targeting IL-17 and TL1A, from Qyuns Therapeutics.
UCB will use Cradle’s AI-driven protein design platform in selected discovery projects, from hit generation through preclinical readiness, expanding its digital antibody engineering program.
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
The half-life-extended antibody failed its primary endpoints in two Phase 2 SKYWAY sub-studies, so Spyre is dropping it in rheumatic diseases and moving it into a combination trial in hidradenitis suppurativa.
Advertisement
Advertisement
Trending on BioPharm International
1
Caldera’s IL-23p19×TL1A Bispecific CLD-423 Shows 40-Day Half-Life in Phase 1a, Supporting Dosing Every 8 to 12 Weeks
2
China Grants Ivonescimab Priority Review in Biliary Tract Cancer
3
VeonGen Aligns with FDA on Phase 3 Design for Stargardt Gene Therapy
4
UCB Partners With Cradle to Apply AI Across Antibody Discovery and Engineering
5